A Phase IB/II,Open Label Study to Assess Efficacy, and Safety, of HS-10542 in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
Latest Information Update: 17 Apr 2026
At a glance
- Drugs HS 10542 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 17 Apr 2026 New trial record